Last reviewed · How we verify
NCT05751603
Effectiveness on Smooth Extubation According to the Administration Time of Sugammadex
NA trial testing sugammadex in Sugammadex in 66 participants. Not yet recruiting.
3 October 2025
Quick facts
| Lead sponsor | Ajou University School of Medicine |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 66 |
| Start date | 3 October 2024 |
| Primary completion | 3 October 2025 |
| Estimated completion | 3 October 2025 |
Drugs / interventions tested
- sugammadex — full drug profile →
Conditions studied
- Sugammadex — all drugs for Sugammadex →
- Extubation — all drugs for Extubation →
- Smooth Emergence — all drugs for Smooth Emergence →
Sponsor
Ajou University School of Medicine
Who can join
Adults 19 to 64, any sex, with Sugammadex or Extubation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
After surgery is completed under general anesthesia, extubation is performed after recovery from anesthesia, and during this process, bucking, coughing, and rapid and excessive hemodynamic fluctuations occur very often. These phenomena can lead to high intrathoracic pressure, venous congestion, hematoma formation, or increased bleeding after major neck surgery. (1) They can also increase the risk of aerosol generation, which can transmit infection to health care workers. (2) For this, smooth extubation is required. Methods of administering drugs such as lidocaine, opioids, or dexmedetomidine have been proposed for smooth extubation. (3-5) As a disadvantage, the use of these drugs may be associated with deep sedation and reduced airway reflexes . Recently, Babu et al. (6) reported that bucking and coughing during extubation could be reduced by changing the timing of administering a muscle relaxant antagonist rather than using these sedative drugs, and thus complications related to extubation could be reduced. In general, in the awakening process, it was common to administer the muscle relaxant at the point of recovery of spontaneous breathing. However, Babu et al. demonstrated the possibility of safe and smooth extubation by changing the timing of administering neostigmine without the use of sedatives or narcotic analgesics, but there are few studies on sugammadex. Therefore, when recovering from general anesthesia, sugammadex was administered before and immediately after extubation to evaluate and compare smooth extubation (ie, comparison of the frequency of bucking and coughing).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05751603
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of sugammadex
Trials testing the same drug.
- NCT06982092 — Using Diaphragm Ultrasonography, Sugammadex Recovers Diaphragmatic Function More Effectively Than Neostigmine. · Phase 1 · completed
- NCT06632067 — Sugammadex and Time to Extubation in Ophthalmic Surgery · completed
- NCT04606901 — Comparison of Time to Extubation Using Sugammadex or Neostigmine · Phase 4 · completed
- NCT05202899 — Effect of Sugammadex for Reversal of Rocuronium-induced Neuromuscular Block on Perioperative Management of Awake Craniot · Phase 4 · unknown
- NCT03112993 — Speed of Recovery of Reversal of Neuromuscular Blockade in Geriatric Patients Undergoing Spine Surgery · Phase 4 · completed
Other recruiting trials for Sugammadex
Currently open trials in the same condition.
- NCT06948409 — NMBA Reversal and Postoperative Urinary Retention · active not recruiting
Other Ajou University School of Medicine trials
Trials by the same sponsor.
- NCT07101380 — Feasibility Study of 'SuperBrain BOOM' for Mild Cognitive Impairment Patients · NA · recruiting
- NCT07395752 — Youth Suicide and Self-Harm Intervention: Clinical and Biological Outcomes Study · NA · recruiting
- NCT06964217 — Immediate Fracture Risk After Antihypertensive Drug Initiation · not yet recruiting
- NCT07479160 — Heart to Heart Web-based Communication Program for Heart Failure · NA · completed
- NCT06295185 — Digital Therapeutic Workplace Technology as a Employee Management Tool and Employee's Mental Health Care · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05751603 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ajou University School of Medicine
- Last refreshed: 25 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05751603.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing